Oncolytic Adenovirus H101
PreclinicalSmall molecule
Oncolytic Adenovirus H101 is one of 54 small molecule programs targeting Malignant Pleural Mesothelioma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
92 competitors in Malignant Pleural Mesothelioma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Gemzar
Johnson & JohnsonPhase 3
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Imfinzi
AstraZenecaPhase 3
Paraplatin
AAvyxa
Phase 3
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Navelbine
PPierre Fabre Medicament
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oncolytic Adenovirus H101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details